Skip to main content
. 2022 Jun 4;41(3):555–567. doi: 10.1200/JCO.21.02370

FIG 4.

FIG 4.

Comparison of (A) AUC and (B) peak of CAR T-cell pharmacokinetics in all evaluable patients with prior bendamustine use (within 6 months, > 12 months, within 12 months, or > 12 months) versus no use. The median is represented by the horizontal line within each box, and the 25th and the 75th percentiles are represented by the lower and upper borders of each box. AUC, area under the curve; benda, bendamustine; CAR, chimeric antigen receptor.